In addition to direct oncolysis, oncolytic viruses (OVs) also induce antitumor immunity, also called viro-immunotherapy. Limited viral replication and immune-negative feedback are the major hurdles to effective viro-immunotherapy. In this study, we found that use of an adjuvant of fludarabine, a chemotherapeutic drug for chronic myeloid leukemia, increased the replication of Newcastle disease virus (NDV) by targeting signal transducer and activator of transcription 1 (STAT1), which led to enhanced oncolysis of hepatocellular carcinoma (HCC) cells. Moreover, fludarabine accelerated ubiquitin-proteasomal degradation by enhancing ubiquitylation rather than proteasomal activity. This resulted in accelerated degradation of phosphorylated STAT3 and indoleamine 2, 3-dioxygenase 1 (IDO1), whose expression was induced by NDV infection. In addition, fludarabine significantly increased the NDV-induced infiltration of NK cells and decreased the number of NDV-induced myeloid-derived suppressor cells (MDSCs) in the tumor microenvironment. The aforementioned effects of fludarabine significantly improved NDVmediated antitumor immunity and prolonged survival in mouse model of HCC. Our findings indicate the utility of fludarabine as an adjuvant for oncolytic anticancer viroimmunotherapy.
INTRODUCTION
Oncolytic virotherapy is a highly promising treatment modality that uses replication-competent viruses to destroy cancers. The approved oncolytic virus T-VEC, a genetically engineered herpes simplex virus-1 (HSV-1) expressing granulocyte-macrophage colony-stimulating factor (GM-CSF), also known as OncoVEX GM-CSF , is a milestone in viro-immunotherapy. 1 Therapeutic oncolytic viruses (OVs) activate antitumor immune responses by inducing immunogenic cell death and type I interferon (IFN)-mediated lymphocyte infiltration. [2] [3] [4] [5] Clinical trials of various OVs such as adenovirus, vaccinia, herpesvirus, reovirus, and paramyxovirus (measles virus and Newcastle disease virus [NDV] ) in advanced cancer patients have shown promise. 6 NDV is a member of the Avulavirus genus of the Paramyxoviridae family. In both preclinical and clinical studies, NDV induced the production of type I IFNs and is an effective oncolytic agent with a good safety record. [7] [8] [9] On one hand, NDV induces both extrinsic and intrinsic apoptosis of malignant cells, 10 and on the other hand, NDV infection elicits both innate and adaptive antiviral immunity, resulting in cross-activated antitumor immune responses. 11, 12 Localized therapy with oncolytic NDV induces an inflammatory response, leading to lymphocyte (NK1.1 + , CD3 + CD8 + , and CD11b + lymphocytes, and monocytes) infiltration and an antitumor effect in distant (nonvirally injected) tumors without dissemination of the virus. The therapeutic efficacy of NDV depends on CD8 + T cells, natural killer (NK) cells and type I IFNs, but not CD4 + lymphocytes. 13, 14 Limited viral replication and immune-negative feedback in the tumor microenvironment (TME) limit the efficacy of viro-immunotherapy for cancer. NDV is an enveloped negative-sense single-strand RNA virus 7 that elicits an antiviral innate immune response via retinoic acid-induced gene I (RIG-I) signaling, which induces the production of type I IFNs and pro-inflammatory cytokines. Signal transducer and activator of transcription 1 (STAT1) amplifies the RIG-I-mediated IFN response to RNA viruses. Several viruses (e.g., hepatitis C virus, simian virus 5, and measles virus) interfere with STAT1 phosphorylation, thereby reducing type I IFN production, which benefits viral replication. [15] [16] [17] Antitumor immune activation is often accompanied by immunenegative feedback, including the production of immunosuppressive cytokines, cell types, and negative co-stimulators. STAT3 plays a key role in generating an immunosuppressive TME by regulating inflammation and various immune cell types including myeloidderived suppressor cells (MDSCs), regulatory T cells (Tregs), and T helper 17 cells (Th17). [18] [19] [20] Hyperactivation of STAT3 signaling occurs in the majority of human cancers and is correlated with a poor prognosis. 21 STAT3 activation is mediated by various cytokines (e.g., interleukin-6 [IL-6], IL-10, and IFNs). Viral infection with, for example, hepatitis C virus, Epstein-Barr virus, and varicella-zoster virus, can activate the STAT3 signaling pathway in host cells. 22 Whether NDV activates STAT3 in hepatocellular carcinoma (HCC) cells is unknown.
Metabolic changes in the TME determine the fate of immune cells such as survival, proliferation, polarization, and activities. 23, 24 Indoleamine 2,3-dioxygenase 1 (IDO1) is highly expressed by dendritic cells, macrophages, MDSCs, and tumor cells and catabolizes the essential amino acid tryptophan into kynurenine. Deprivation of tryptophan and accumulation of kynurenine and its metabolic product 3-hydroxyanthranilic acid lead to apoptosis or dysfunction of effector T cells and induction of Tregs, respectively. [25] [26] [27] In some tumors, including those of the prostate, breast, brain, and blood, IDO1 is constitutively expressed and contributes to cancer-associated immune suppression. 26, 28 IDO1 can be elicited by inflammatory factors, such as IFNs, 26, 28 or viral infection, such as measles virus and hepatitis C virus, 29, 30 and reduces the intensity of potentially deleterious immune responses. Clinical trials of IDO1 inhibitors, including indoximod, epacadostat, and NLG919 for multiple oncology indications are currently underway. 26, 31 Fludarabine is a purine analog used to treat leukemia and lymphoma that inhibits DNA synthesis by interfering with ribonucleotide reductase and DNA polymerase. 32 Fludarabine is an inhibitor of STAT1, which prevents overproduction of type I IFNs. 33 Moreover, fludarabine decreases IDO in malignant cells by proteasome-mediated degradation. 34 We and another group found that fludarabine reduces IDO1 expression therefore enhances the antitumor activity of adoptive T cells. 30, 35 It is yet unknown if fludarabine downregulates STAT3 signaling. Effective antitumor immunotherapy requires both immune activation and prevention of immunosuppression. Given its multiple functions, we hypothesized that fludarabine would be a powerful adjuvant for oncolytic viro-immunotherapy. In this study, we employed oncolytic NDV to activate antitumor immunity and used fludarabine as an adjuvant to enhance NDV replication and prevent concomitant immunosuppression in HCC.
RESULTS

Fludarabine Enhances NDV-Mediated Oncolysis in HCC Cells
Fludarabine and NDV had dose-dependent cytotoxic effects on human and murine HCC cells ( Figures 1A and 1B) . Indeed, 200 nM fludarabine together with NDV at an MOI of 10 resulted in slight cytotoxic effects. Fludarabine dramatically enhanced the NDVinduced oncolysis of HCC cells ( Figures 1C and 1D) . Moreover, fludarabine and NDV significantly increased the number of annexin V-positive (apoptotic) cells ( Figure S1 ), which indicates that fludarabine markedly enhances NDV-induced apoptotic cell death. Therefore, fludarabine significantly enhances the NDV-mediated oncolysis of HCC cells. Next, we quantified NDV replication by determining the viral production and the expression levels of Ndv-hn (hemagglutinin-neuraminidase) and Ndv-m (matrix) genes. Fludarabine (200 nM) increased NDV replication 2-to 6-fold in HCC cells at 24 h after infection (Figures 2A and 2B ). We then evaluated the expression of Ifnb (IFN-b) and Cxcl10 (C-X-C motif chemokine 10), key cellular innate antiviral factors. Viral infection was unaffected by fludarabine ( Figure S2 ), however, Ifnb and Cxcl10 expression were significantly reduced by fludarabine at 6 h after infection ( Figures 2C  and 2D ), suggesting that fludarabine may promote viral replication by mitigating antiviral innate immunity.
To further clarify how fludarabine downregulated Ifnb and Cxcl10 expression in cells, we assessed the activation of STAT1. In Figure 3A ). Interestingly, NDV-induced STAT3 activation was markedly reduced by fludarabine ( Figure 3B ). In addition, the expression of Il-6, a pro-tumor inflammatory cytokine and downstream target of STAT3, was markedly upregulated by NDV but was reduced by fludarabine to ca. 50% to 70% ( Figure 3C ). These results suggest that fludarabine ameliorates NDV-induced inflammation by targeting STAT3 signaling in HCC cells. Next, we evaluated the mechanism by which fludarabine promotes degradation of p-STAT3. First, we investigated the role of STAT1. In STAT1-silenced HCC cells, the p-STAT3 level was not reduced by viral infection, and the fludarabine-induced decrease in p-STAT3 level was not recovered (Figure 3D ). These data suggest that STAT1 signaling is not involved in the fludarabine-mediated inhibition of p-STAT3 in HCC cells. Second, we evaluated the role of autophagy in fludarabine-induced p-STAT3 degradation. At 2, 6, 12, and 24 h, we determined the ratio of microtubule-associated proteins 1A/1B light chain 3B (LC3-II/I). However, fludarabine did not increase the LC3-II/I ratio (a marker of autophagosome formation) in HCC cells ( Figure 3G , lower), which indicates that p-STAT3 is not degraded in the autophagosome. However, in NDV infected HCC cells, the fludarabine induced reduction in p-STAT3 level was almost completely blocked by the proteasome inhibitor MG132 ( Figure 3E ), which indicates that proteasomal degradation is involved in the elimination of p-STAT3. Moreover, cellular proteasomal activity was not altered by fludarabine in infected or uninfected HCC cells ( Figure 3F ). However, the levels of polyubiquitinated proteins, particularly those of similar size to p-STAT3 (75-100 kDa; Figure 3G ) were affected by fludarabine. Following fludarabine treatment, the levels of polyubiquitinated proteins increased at 2 and 6 h and decreased at 12 and 24 h; the p-STAT3 level was also decreased at the latter two time points ( Figure 3G, left) . Therefore, fludarabine induces ubiquitin-proteasomal degradation of p-STAT3.
Fludarabine Antagonizes NDV-Induced IDO1 by Promoting Proteasomal Degradation IDO1 plays a crucial role in tumor-associated immunosuppression and is upregulated during an immune response. IDO1 protein and mRNA levels were significantly increased in NDV-infected HCC cells ( Figures 4A and 4B ). Fludarabine dramatically decreased the NDVinduced increase in IDO1 level ( Figure 4C ). Interestingly, fludarabine significantly increased Ido1 mRNA expression in NDV-infected LM3 and Hepa1-6 HCC cells ( Figure 4D ). Moreover, in HCC cells treated with fludarabine and MG132, IDO1 expression was almost completely recovered ( Figure 4E ). Therefore, fludarabine promotes proteasomal degradation of IDO1 in NDV-infected HCC cells.
Fludarabine Increases NDV Replication In Vivo and Enhances NDV-Mediated Antitumor Immunity
In a mouse model of ascitic HCC ( Figure 5A ), fludarabine increased NDV replication 2-to 13-fold in ascitic cells on days 12 and 16 after tumor transplantation ( Figures 5B and 5C ) and markedly promoted p-STAT3 and IDO1 degradation (Figures 5D). Moreover, NDV induced an overall immune response in ascites, which was significantly increased by fludarabine ( Figure 5E ). Consistently, Ifnb, Cxcl10, and Ifnb expression was significantly upregulated by NDV and further increased by fludarabine ( Figure 5F ). Moreover, CD8 + T and NK1.1 + cell infiltration in ascites was increased almost 2-fold by NDV (Figures 5G and 5H) . Interestingly, infiltration of NK cells, but not CD8 + T cells, was further significantly increased by fludarabine ( Figures 5G and 5H) . Notably, fludarabine at 7.5 mg/mouse did not have significant cytotoxic effects on CD8 + T and NK cells ( Figures 5G and 5H) . Surprisingly, NDV increased the number of MDSCs in ascites (CD11b + Gr-1 int ); importantly, fludarabine antagonized this effect ( Figure 5I ). Thus, fludarabine increases the oncolytic effects of NDV by upregulating viral replication, promoting degradation of p-STAT3 and IDO1, increasing NK cell infiltration, and reducing the number of MDSCs.
Fludarabine Enhances the Antitumor Efficacy of NDV
Next, we investigated the antitumor efficacy of NDV plus fludarabine in vivo. In the ascitic HCC model ( Figure 6A ), fludarabine enhanced the antitumor efficacy of NDV (Figures 6B and S5B) resulting in prolonged survival ( Figure 6C ). Of note, the abdomen circumference was markedly reduced in two of seven mice ( Figure S5A ), and one mouse acquired a complete response to the combination treatment (Figure 6C) . In a subcutaneous HCC model ( Figure 6D ), fludarabine significantly enhanced the therapeutic efficacy of NDV ( Figure 6E ) and prolonged the survival. Three out of seven mice obtained completed responses to the combination treatment ( Figure 6F ). No obvious therapy-associated side effect or body-weight loss was recorded ( Figures S5C and S5D ). These results indicate that fludarabine improves the antitumor efficacy of NDV.
Fludarabine Antagonizes IFN-g-Induced STAT3 Activation and Upregulation of IDO1
Negative feedback plays a crucial role in immune homeostasis and cancer-associated immune suppression. We further determined the influence of fludarabine on p-STAT3 and IDO1 in the presence of IFN-g, which was upregulated by NDV ( Figure 5E ). , 12, or 24 h and lysed, and the polyubiquitinated protein, STAT3, p-STAT3, and LC3-I/II levels were determined by western blotting. GAPDH was used as a loading control. *p < 0.05; **p < 0.01; ***p < 0.001; #not significant.
enhanced NDV-mediated viro-immunotherapy by promoting viral replication by targeting STAT1, which enhanced oncolysis, and promoting NDV-induced antitumor immune responses by accelerating the ubiquitin-proteasomal degradation of p-STAT3 and IDO1, increasing NK cell infiltration and reducing the number of MDSCs in the TME (Figure 8 ). Thus, fludarabine and NDV represent a promising oncolytic viro-immunotherapy.
Efficient replication in cancer cells is a crucial determinant for oncolytic virotherapy. Viral replication is mainly dependent on cell viability and host cellular antiviral innate immunity. Replication of oncolytic measles virus in lymphoma cells was increased by fludarabine; however, the mechanism is unknown. 36 In this study, fludarabine at a low dose had little impact on cell viability but significantly enhanced NDV replication. We previously reported that autophagic flux favored oncolytic NDV replication by preventing virus-induced apoptosis. 37 Fludarabine did not induce de novo formation of autophagosomes. Type I IFNs induce STAT1 expression as a part of positive feedback loop to augment the extent and duration of IFN responses, 38-41 which may limit viral replication. 15, 42 Thus, as an inhibitor of STAT1, 33 fludarabine promoted NDV replication by suppressing the production of type I IFNs at the early stage ( Figure 2C ). However, when more viral yields were generated, the production of type I IFNs was increased accordingly (Figures 5F and S4) , which may further participate in immune activation. (B and C) Ascitic cells were harvested at days 12 and 16, Ndv-hn and Ndv-m expression was quantified by qPCR (B), and NDV titers were measured by plaque assay (C).
(legend continued on next page)
Activated STAT3 and IDO1 participate in cancer-associated immunosuppression, 21, 26, 43 and their expression in cancer cells is induced by immune stimulation such as viral infection, IFNs, and adoptive immune cell therapy. 34 Elevated levels of p-STAT3 and IDO1 are detrimental to viro-immunotherapy. Fludarabine is suitable for oncolytic viro-immunotherapy, as it suppressed NDV-activated IL-6/ STAT3 signaling and IDO1 upregulation. Moreover, fludarabine significantly reduced p-STAT3 and IDO1 expression in HCC cells treated with IFN-g, the level of which is markedly elevated during an antitumor immune response. Activated STAT3 is mainly degraded via the ubiquitin-proteasome pathway. [44] [45] [46] [47] In line, we found that fludarabine promoted proteasomal degradation of p-STAT3 in HCC cells, not by increased activity of proteasome but by enhanced ubiquitination of the target protein. Similarly, fludarabine accelerated the NDV-or IFN-g-induced ubiquitin-proteasomal degradation of IDO1 in HCC cells. A previous study showed that IDO1 participated in IFN-g-mediated antiviral effect, 48 it would be interesting to know if NDV replication might also benefit from enhanced degradation of IDO1 by fludarabine observed in vivo.
NDV elicits both an innate and adaptive immune response in the TME by inducing IFN production and immune cell infiltration and maturation. [7] [8] [9] 11, 12 In this study, local injection of NDV in HCC induced an immune response and infiltration of CD8 + T and NK cells in the TME. Indeed, fludarabine enhanced overall immune response induced by NDV in the ascitic fluid. Direct activation of NK cells contributes to the antitumor effects of NDV. 49 NDV-induced NK-cell infiltration was further increased by fludarabine, possibly by increasing NDV replication.
Immunosuppressive MDSCs comprise granulocytic CD11b
+ Gr-1 high cells and monocytic CD11b + Gr-1 int cells, the latter subset of which is most suppressive. NDV infection induced polarization of monocytes to CD11b + Gr-1 int MDSCs, which may repress antitumor immunity. Surprisingly, fludarabine significantly decreased the number of MDSCs in the TME. Because the differentiation of MDSCs depends on STAT3 activation, 18 this decrease in the number of MDSCs was likely due to accelerated degradation of p-STAT3. Furthermore, as IDO1 is correlated with the expansion, recruitment, and activation of MDSCs in tumors, 50 the fludarabine-induced decrease in IDO1 expression might also have led to a reduction in the number of MDSCs. The ascitic HCC tumor model used in this study facilitates dynamic monitoring of viral replication, oncolysis, immune activation, and cell infiltration. Finally, the antitumor potency of fludarabine with NDV was validated in a subcutaneous HCC tumor model.
In conclusion, NDV induced an antitumor immune response in the TME as well as negative feedback, such as STAT3 activation, and increased IDO1 and MDSCs. Fludarabine not only promotes viral replication by targeting STAT1 but also accelerates proteasomal degradation of p-STAT3 and IDO1 and reduces the number of infiltrating MDSCs. These effects of fludarabine significantly prolong the survival of HCC-bearing mice. Our findings suggest the potential of fludarabine as an adjuvant for oncolytic viro-immunotherapy, but further work is required before it can be used clinically.
MATERIALS AND METHODS
Cell Culture and Reagents
The human HCC cell line HCCLM3 and mouse HCC cell line H22 were obtained from the China Center for Type Culture Collection; the human HCC cell line HepG2 and mouse HCC cell line Hepa1-6 were obtained from the Cell Bank of Type Culture Collection Chinese Academy of Sciences. These cell lines were authenticated by short tandem repeat (STR) analysis and tested for mycoplasma contamination. HCCLM3 (abbreviated LM3), HepG2, and Hepa1-6 cells were cultured in DMEM, whereas H22 cells were cultured in RPMI 1640, supplemented with 10% fetal bovine serum (FBS), 2 mM L-glutamine, 100 units/mL penicillin, and 0.1 mg/mL streptomycin (all from Thermo Fisher Scientific, Gibco, Grand Island, NY, USA), and maintained in a humidified incubator with atmosphere containing 5% CO 2 at 37 C.
The following reagents were used in this study: fludarabine monophosphate (#F0913; Tokyo Chemical Industry, Tokyo, Japan), MG132 (#M8699; Sigma-Aldrich, St. Louis, MO, USA), human IFN-g (#Z02915; GenScript, Piscataway, NJ, USA), trypan blue (#ST798; Beyotime Biotechnology, Shanghai, China), and 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) (#M2128; Sigma-Aldrich).
NDV Propagation, Viral Titers, and Infection
The NDV La Sota strain was a gift from Prof. Y. Wang (Jiangsu Academy of Agricultural Sciences, China), propagated in 9-dayold specific-pathogen-free (SPF) embryonated chicken eggs from seed virus, harvested from the allantoic fluid, and purified by centrifugation at 3,000 rpm for 10 min. The viral particles in the supernatant were harvested and cryopreserved at À80 C. Viral titers were determined by plaque assay. In brief, samples were serially diluted, and 100 mL of each dilution was added per well to Vero cells in 12-well plates. 2 h later, DMEM (containing 2 mg/mL N-tosyl-Lphenylalanine chloromethyl ketone [TPCK]-treated trypsin, 2% FBS, and 0.8% agar) was added and cells were incubated at 37 C for 4 days. Then cells were fixed with 4% paraformaldehyde solution and stained with 0.5% neutral red solution for observation of plaques.
Tumor cells were washed once with PBS and infected with NDV in OptiMEM (Thermo Fisher Scientific, Gibco) at the indicated MOI for 2 h, and complete medium was added to each well.
Cytotoxic Effect Assay MTT Cell Viability Assay
Cells were seeded in 96-well plates and treated with fludarabine, NDV, or both at the indicated doses. Cell viability was determined after 48 h of incubation by adding 100 mL MTT solution (1 mg/mL). Following 4 h incubation at 37 C, the MTT solution was aspirated and 150 mL isopropanol were added to solubilize formazan, followed by shaking for 15 min. The absorbance at 570 nm was recorded using the SpectraMax M3 Multi-Mode Microplate Reader (Molecular Devices, Sunnyvale, CA, USA).
Trypan Blue Exclusion
Cells were harvested using trypsin-EDTA (0.25%) solution (Thermo Fisher Scientific, Gibco) and stained with trypan blue solution; viability was determined by trypan blue exclusion using the Countstar Automated Cell Counter (Inno-Alliance Biotech, Wilmington, DE, USA). The cell death (%) was calculated as number of dead cells/total number of cells Â 100%. The cell activity (%) was calculated as number of live cells/total number of cells Â 100%. Table S1 . NDV infection or drug treatment was performed at 24 h after siRNA transfection in STAT1-silencing experiments.
Animal Experiments and Tumor Models
Six-week-old male C57BL/6 mice were obtained from the Model Animal Research Center of Nanjing University (Nanjing, China). Experiments were conducted according to the ethical guidelines approved by the local government.
The Ascitic HCC Tumor Model
For immune-activation experiments, tumors were implanted by intraperitoneal (ip.) injection of 2 Â 10 6 H22 cells on day 0. H22-bearing mice were randomized to four groups on day 2. On days 2, 9, and 15, the mice received an ip. injection of 1 Â 10 7 plaqueforming units (pfu) of NDV per mouse in PBS in a total volume of 100 mL, followed 1 h later by ip. injection of 0.75 mg/mouse fludarabine monophosphate solution in a total volume of 100 mL. The control groups received an equal volume of PBS intraperitoneally. On days 12 and 16, ascites samples (500 mL) were removed for determination of NDV replication, antiviral gene expression, immune cell infiltration, IFN-g enzyme-linked immune absorbent spots (ELISpots), IDO1 expression, and STAT3 phosphorylation. For oncolysis and survival experiments, tumors were implanted by ip. injection of 5 Â 10 6 H22 cells on day 0. H22-bearing mice were randomized to four groups on day 2. On days 2, 3, 7, 8, 12, and 13, the mice received an ip. injection of 1 Â 10 7 pfu of NDV per mouse in PBS in a total volume of 100 mL, followed 1 h later by an ip. injection of 0.75 mg/mouse fludarabine monophosphate solution in a total volume of 100 mL. The control groups received an equal volume of PBS intraperitoneally. On days 12 and 16, ascites samples (100 mL) were removed for determination of cell number and activity. The body weight and behaviors of the mice were monitored every other day, and their survival was monitored daily.
The Subcutaneous HCC Tumor Model 6-to 8-week-old male C57/BL6 mice received subcutaneous injection of 5 Â 10 6 Hepa1-6 cells of each. On days 7, 10, and 13, the mice received intratumoral (it.) injection of 1 Â 10 7 pfu NDV per mouse, respectively. On days 7 and 13, the mice received intraperitoneal injection of 0.75 mg/mouse fludarabine monophosphate solution in a total volume of 100 mL. + T cells (cytotoxic T lymphocytes). Samples were subjected to flow cytometry using a FACS Calibur instrument (BD Biosciences), and data were analyzed using FlowJo software (v. 7.6.5, Tree Star, Ashland, OR, USA).
Proteasome Activity Assay
Proteasome activity was monitored based on the release of fluorescent 7-amido-4-methylcoumarin (AMC) from its tagged peptide substrate using a proteasome activity fluorometric assay kit (#K245-100; BioVision, Milpitas, CA, USA) according to the manufacturer's instructions. In brief, following treatment, cells were lysed with 0.5% NP-40. AMC standards, positive controls, and samples diluted in assay buffer were loaded in duplicate into a 96-well plate. The fluorescence activity was measured using the SpectraMax M3 Multi-Mode Microplate Reader at 37 C for 60 min at excitation and emission wavelengths of 350 and 445 nm, respectively. Proteasome activity was determined based on the standard curve.
IFN-g Enzyme-Linked Immunosorbent Spot Assay
The activation status of immune cells in ascites was evaluated by the mouse IFN-g EILSpot PLUS kit (3321-2AW-Plus; Mabtech, Nacka Strand, Sweden) according to the manufacturer's protocols. In brief, ascites cells were seeded in a 96-well plate coated with an IFN-g capture antibody at a density of 2 Â 10 5 cells/well at 37 C for 24 h in a humidified incubator with an atmosphere containing 5% CO 2 . The cells were removed, the plate was washed five times with PBS, a biotinylated anti-IFN-g antibody was added, and the plate was incubated at room temperature for 2 h. Next, the plate was washed with PBS, streptavidin-ALP was added, and the plate was incubated at room temperature for 1 h. Finally, the BCIP/NBT-plus substrate was added until spots emerged, and the plate was washed with tap water to stop the reaction. The plate was analyzed using an enzyme-linked immunosorbent spot (ELISpot) reader (Autoimmun Diagnostika, Strassberg, Germany) to enumerate spots, and spot activity was characterized as the weighted average of the spot size and intensity in a well. 30 
Statistical Analyses
Data were analyzed by the two-tailed unpaired Student's t test (for comparisons of two groups). Survival data were analyzed by the log rank (Mantel-Cox) test. Statistical analyses were conducted using Microsoft Excel (Microsoft, Redmond, WA, USA) or Prism software (v. 6.01; GraphPad). 
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